Prime Therapeutics’ recently issued annual drug trend results show commercial clients saw a 3.3% trend in 2018, while year-over-year trends for Medicare Part D and Medicaid plans were 4.7% and 7.3%, respectively. Despite increases year over year in utilization and spend, especially for specialty drugs, across all lines of business, the Eagan, Minn.-based PBM said it has been “consistently able to help lessen the cost burden for health plans and their members.”
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.